Typical Electronic Health Record Use in Primary Care Practices and the Quality of Diabetes Care
INTRODUCTION: Encouraging the adoption of electronic health records (EHRs) in primary care settings has been an objective of federal health policy since 2004, when the Bush administration set the goal of universal EHR use within 10 years. Since that time, the use of EHR technology has been identified as a central component of the patient-centered medical home model endorsed by primary care professional organizations in the United States.1,2 Through passage of the Health Information Technology for Economic and Clinical Health (HITECH) Act in 2009, Congress and the Obama administration have reaffirmed the objective of increasing adoption of ambulatory care EHRs. HITECH includes incentives for physicians to implement and “meaningfully use” EHR technology, and has funded Regional Extension Centers (RECs) to assist care providers in meeting these objectives.3,4 Underlying these policy developments is the assumption that EHR use, if meaningful, will improve the safety, quality, and efficiency of the US health care system.
PURPOSE: Recent efforts to encourage meaningful use of electronic health records (EHRs) assume that widespread adoption will improve the quality of ambulatory care, especially for complex clinical conditions such as diabetes. Cross-sectional studies of typical uses of commercially available ambulatory EHRs provide conflicting evidence for an association between EHR use and improved care, and effects of longer-term EHR use in community-based primary care settings on the quality of care are not well understood.
METHODS: We analyzed data from 16 EHR-using and 26 non–EHR-using practices in 2 northeastern states participating in a group-randomized quality improvement trial. Measures of care were assessed for 798 patients with diabetes. We used hierarchical linear models to examine the relationship between EHR use and adherence to evidence-based diabetes care guidelines, and hierarchical logistic models to compare rates of improvement over 3 years.
CLICK SOURCE FOR MORE….
IMAGES: www.siliconangle.com
Related articles
- Tech Companies Tackling Electronic Health Records (betakit.com)
- All PC makers sales drop dramatically, except Apple (efficientmd.blogspot.com)
- Why Don’t More Hospitals Use Electronic Health Records? (businessweek.com)
- What to do when EHR fails (healthcareitstrategy.com)
HCG Ultra Drops to Help Your Weight Drop
Dietary options today can cost a health-conscious American thousands of dollars each year, and the results may be short-lived. And like you have probably already seen, they are all over the internet in blogs and success stories of people who have apparently used diet aids and lost a ton of weight. But we here at Fox News are a little skeptical and aren’t sure that we’ve seen any real proof that these diet aids work for weight loss. So we decided to put these products to the test. What better way to find out the truth than to conduct our own study?
To get started, I volunteered to be the guinea pig. I applied for 2 bottles of HCG Ultra. While there are tons of diet aid ads online, HCG Ultra is one of the most credible and trustworthy suppliers on the market. Another reason why I chose HCG Ultra is because it comes with a 30-day money back guarantee – easily the longest on the market. With nothing to lose, I decided to take the plunge.
Here is what HCG Ultra claims on their website…
- Lose 1-2 Pounds Daily! Permanently!
- No Hunger Pains, Maintain Muscle Tone, Feel Great!
- Equally as Effective as Clinical Injections. Save Money & NO Pain!
- Made in the USA! FDA Compliant! All Natural & Completely Safe!
- HCG Ultra is YOUR Solution! Guaranteed Results!
CLICK SOURCE FOR FULL STORY
Reviving Vaccines Production in Nigeria
It’s a move aimed at bridging the gap between demand and supply of vaccines in Nigeria. May & Baker, one of Nigeria’s foremost pharmaceutical company, has concluded plans to begin production of routine vaccines such as Bacillus Chalmette Guerin, BCG, hepatitis and diphtheria, tetanus and pertusis, DPT; oral polio vaccine, OPV, measles and yellow fever, in Nigeria.
But this is an effort that started in 2005 when May & Baker signed a memorandum of understanding, MOU, with the Federal Ministry of Health to revitalise the moribund Federal Vaccine Production Laboratory, FVPL, Yaba, Lagos. By 2007, the company, in partnership with the federal government renewed a joint venture agreement, JVA, that led to the establishment of a company named Biovaccines Nigeria Limited, for the production of vaccines in Nigeria. Now, the pharmaceutical company has commenced construction of a new vaccine plant to be sited in Ota, Ogun State, with a view to starting production of yellow fever vaccines within 18 months.
Nnamdi Okafor, managing director and chief executive officer, CEO, May & Baker, said the company went into local production of vaccines, because it had always desired to show the way forward for the health care industry.
healthylifeconsult 